Thor Medical ASA (TRMED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Thor Medical ASA (TRMED) has a cash flow conversion efficiency ratio of 0.000x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-5.74K ≈ $-603.91 USD) by net assets (Nkr337.10 Million ≈ $35.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Thor Medical ASA (TRMED) net asset quality to measure how much of total assets are equity-financed.
Thor Medical ASA - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Thor Medical ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Thor Medical ASA (TRMED) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Thor Medical ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Thor Medical ASA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kore Potash Plc
AU:KP2
|
-0.004x |
|
Immersion Corporation
NASDAQ:IMMR
|
-0.060x |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
-0.326x |
|
Ample Electronic Technology Co Ltd
TWO:4760
|
-0.014x |
|
GOCL Corporation Limited
NSE:GOCLCORP
|
-0.008x |
|
Ontex Group NV
BR:ONTEX
|
0.072x |
|
Rhom Bho Property Public Company Limited
BK:TITLE
|
-0.254x |
|
Ascom Holding AG
SW:ASCN
|
0.143x |
Annual Cash Flow Conversion Efficiency for Thor Medical ASA (2020–2024)
The table below shows the annual cash flow conversion efficiency of Thor Medical ASA from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see TRMED market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr337.10 Million ≈ $35.47 Million |
Nkr-23.70 Million ≈ $-2.49 Million |
-0.070x | +70.17% |
| 2023-12-31 | Nkr271.93 Million ≈ $28.61 Million |
Nkr-64.09 Million ≈ $-6.74 Million |
-0.236x | +96.32% |
| 2022-12-31 | Nkr63.84 Million ≈ $6.72 Million |
Nkr-409.08 Million ≈ $-43.05 Million |
-6.408x | -123.17% |
| 2021-12-31 | Nkr140.52 Million ≈ $14.79 Million |
Nkr-403.46 Million ≈ $-42.46 Million |
-2.871x | -28.83% |
| 2020-12-31 | Nkr178.67 Million ≈ $18.80 Million |
Nkr-398.21 Million ≈ $-41.90 Million |
-2.229x | -- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.